Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Andres Forero-Torres, Paul M. Barr, Catherine S. Magid Diefenbach, Taimur Sher, Richard Schaub, Li Zhou, Jennifer Pulini, Lance Leopold, Matthew A. Spear, Moshe Talpaz, Tycel Jovelle Phillips | ||||||||||||
Title | A phase 1 study of INCB040093, a PI3K? inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/146209-156 | ||||||||||||
Abstract Text | J Clin Oncol 33, 2015 (suppl; abstr 8558) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|